Please ensure Javascript is enabled for purposes of website accessibility

Why Pfizer, BioNTech, and Moderna Stocks Jumped Today

By Joe Tenebruso – Aug 23, 2021 at 4:41PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A major regulatory approval sparked a rally in coronavirus vaccine stocks.

What happened 

The U.S. Food and Drug Administration (FDA) approved Comirnaty -- the COVID-19 vaccine co-developed by Pfizer (PFE 0.74%) and BioNTech (BNTX -0.88%) -- for use in people aged 16 and older on Monday. The news drove shares of Pfizer and BioNTech up 2.5% and 9.6%, respectively. Fellow vaccine maker Moderna (MRNA -0.23%) also saw its stock price surge 7.6%.

So what

The decision marks the first time the FDA has granted full approval for a COVID-19 vaccine. Previously, Pfizer's and BioNTech's vaccine was being administered under an emergency use authorization. Moderna's and Johnson & Johnson's drugs have also received an EUA.

The approval comes at a time when COVID-19 cases counts are surging, driven in part by new coronavirus mutations such as the delta variant.

"Based on the longer-term follow-up data that we submitted, today's decision by the FDA affirms the efficacy and safety profile of our vaccine at a time when it is urgently needed," Pfizer CEO Albert Bourla said in a press release. "About 60% of eligible Americans are fully vaccinated, and infection, hospitalization, and death rates continue to rise rapidly among unvaccinated populations across the country."

A healthcare worker is administering a vaccine to a patient.

Image source: Getty Images.

Bourla believes that the approval could spur more people to get vaccinated. "I am hopeful this approval will help increase confidence in our vaccine, as vaccination remains the best tool we have to help protect lives and achieve herd immunity," Bourla said.

Now what 

The approval will likely result in more sales and profits for Pfizer and BioNTech. The approval also bodes well for Moderna, which used similar mRNA technology to develop its COVID-19 vaccine and achieved a comparable efficacy and safety profile to Pfizer's and BioNTech's drug. Investors, in turn, bid up shares of all three of these drugmakers today.

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson and Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Stock Quote
Pfizer
PFE
$49.21 (0.74%) $0.36
Moderna Inc. Stock Quote
Moderna Inc.
MRNA
$176.40 (-0.23%) $0.41
BioNTech SE Stock Quote
BioNTech SE
BNTX
$154.85 (-0.88%) $-1.38

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
360%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.